Renew has developed a novel enzymatic platform by synthetic biology to create a diverse pipeline of proprietary therapeutic molecules (i.e. alkylresorcinol scaffold derivatives; similar to CBGA). Uniquely, Renew’s scaffold molecules pass the blood brain barrier and engage a classic cellular receptor that controls inflammation (i.e. PPAPγ), together making this family of molecules particularly useful for indications of neuro-therapeutics. Renew is specifically focused on developing therapeutics to treat neuroinflammation pathologies, with specific focus on Traumatic Brain Injury (TBI). No drug treatment is currently approved by the FDA for TBI, while millions of patients from all age groups are effected worldwide annually. Renew’s proprietary “enzymatic chemistry” processes are in stark contrast to traditional “medicinal chemistry” processes commonly employed by Big Pharma. While traditional medicinal chemistry often requires noxious reaction components and exhibits low synthesis efficiencies, Renew’s custom engineered “enzymatic reactions” are highly efficient and scalable. These enzymatic reactions are particularly amenable for alkylresorcinol scaffold derivative molecules (that require prenylation-type synthesis). Renew’s platform for creating therapeutic derivatives by engineered enzymes is covered by a robust IP portfolio related to key enzymes (and engineered variants thereof) for production of alkylresorcinol derivatives by prenylation processes.